Fresenius Kabi agreed to buy a majority stake in the mAbxience division of Spain’s Insud Pharma to expand the generic drug unit’s business making cheaper versions of biotechnology products that have lost patent protection. Fresenius said Kabi also agreed to acquire Ivenix Inc., a maker of infusion therapies.


Bayer said the German drugmaker would invest around 2 billion euros ($2.23 billion) at pharmaceutical manufacturing sites over the next three years, mainly to bolster production of biotechnology products as well as cell and gene therapies.

Aside from vaccines, the advent of several effective COVID-19 antiviral therapies, including Pfizer’s Paxlovid, provides hope for ending the pandemic. Details about the U.S. government’s contract with Pfizer for 10 million doses of Paxlovid are emerging, with some unusual elements.

Allogene Therapeutics is halting the clinical trial for the company’s AlloCAR T cancer therapy after finding some chromosomal abnormality in a patient.

Artificial Intelligence (AI) is at the forefront of modern technology and has begun to parallel in the world of biotechnology. Many biopharma companies are using AI to drive innovation, enhance their processes and explore new business models.

ERT, a global leader in clinical endpoint data solutions, on April 28 announced the close of the company’s merger with Bioclinica, a technological and scientific leader in clinical imaging.

Bristol Myers Squibb

Bristol Myers Squibb announced plans for a new manufacturing plant in Devens, Mass., adding to the company’s cell therapy network.

Fishawack Health announced the acquisition of The Hive Health Group, a London and New York-based healthcare marketing and scientific communications agency.

Heron Therapeutics Inc.’s New Drug Application (NDA) was resubmitted to the U.S. Food and Drug Administration for HTX-011, an investigational agent for the management of postoperative pain.

The Healthcare Technology Report announced the Top 25 Women Leaders in Biotechnology of 2020.